Capture

KYMRIAH, CAR-T cell immunotherapy- an entirely new treatment approach for patients with cancer FDA Approvals: KYMRIAH, MYLOTARG, VABOMERE, Benznidazole

  • Produced by taking patient’s blood sample, isolating T lymphocytes, and genetically engineering those T-cells to express a new chimeric receptor that recognizes CD19 on their leukemia and normal B-cells
  • Engineered T-cell should recognize and kill B-cells, including the malignant cells

LISTEN


Image credit: FDA


Leave a Reply


Fill in your details below or click an icon to log in:

WordPress.com Logo



You are commenting using your WordPress.com account.
Log Out / 
Change )

Google photo



You are commenting using your Google account.
Log Out / 
Change )

Twitter picture



You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo



You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s